Ponatinib in chronic myeloid leukaemia: ready for first-line?

被引：0
|
作者：
Breccia, Massimo [1 ]
Alimena, Giuliana [1 ]
机构：
[1] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00161 Rome, Italy
来源：
LANCET HAEMATOLOGY | 2015年 / 2卷 / 09期
关键词：
FOLLOW-UP; IMATINIB;
D O I：
10.1016/S2352-3026(15)00130-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E352 / E353
页数：2
相关论文
共 50 条
  • [1] Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study
    Jain, Preetesh
    Kantarjian, Hagop
    Jabbour, Elias
    Gonzalez, Graciela Nogueras
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    Gachimova, Evguenia
    Ferrajoli, Alessandra
    Kornblau, Steven
    Ravandi, Farhad
    O'Brien, Susan
    Cortes, Jorge
    LANCET HAEMATOLOGY, 2015, 2 (09): : E376 - E383
  • [2] Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)
    Abruzzese, Elisabetta
    Breccia, Massimo
    Latagliata, Roberto
    BIODRUGS, 2014, 28 (01) : 17 - 26
  • [3] The true value of second-generation TKIs as first-line therapy in chronic myeloid leukaemia
    Andrews, Claire N.
    Lipton, Jeffrey
    LANCET HAEMATOLOGY, 2019, 6 (08): : E385 - E386
  • [4] Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)
    Elisabetta Abruzzese
    Massimo Breccia
    Roberto Latagliata
    BioDrugs, 2014, 28 : 17 - 26
  • [5] Cost effectiveness of imatinib compared with interferon-α or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia
    Kim Dalziel
    Ali Round
    Ruth Garside
    Ken Stein
    PharmacoEconomics, 2005, 23 : 515 - 526
  • [6] Nilotinib In the First-Line Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia in Chronic Phase
    Garnock-Jones, Karly P.
    DRUGS, 2011, 71 (12) : 1579 - 1590
  • [7] NilotinibIn the First-Line Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia in Chronic Phase
    Karly P. Garnock-Jones
    Drugs, 2011, 71 : 1579 - 1590
  • [8] Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study
    Etienne, Gabriel
    Huguet, Francoise
    Guerci-Bresler, Agnes
    Nicolini, Franck E.
    Maloisel, Frederic
    Coiteux, Valerie
    Dauriac, Charles
    Carpentier, Nathalie
    Bourdeix, Isabelle
    Tulliez, Michel
    Cony-Makhoul, Pascale
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (01) : 71 - 80
  • [9] Nilotinib as first-line therapy for chronic myeloid leukemia
    Vaid, A.
    INDIAN JOURNAL OF CANCER, 2011, 48 (04) : 438 - 445
  • [10] Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
    Molica, Matteo
    Scalzulli, Emilia
    Colafigli, Gioia
    Foa, Robin
    Breccia, Massimo
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10
12345